Dual immunotherapy plus chemotherapy for stomach cancer
Part of Cancer clinical trials.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stomach cancer or cancer at the junction of the stomach and esophagus that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer is HER2-negative (a specific marker on tumor cells).
- You have not had prior chemotherapy or other cancer treatment for this advanced stage; if you had treatment before surgery, it must have finished at least 12 months earlier.
- You have at least one measurable tumor (on imaging tests).
- You are generally healthy enough to do daily activities (ECOG 0 or 1) and have adequate organ function (heart, liver, kidneys, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which blocks blood vessel growth to tumors), and chemotherapy for people with a specific type of stomach cancer that is MSI-H/dMMR (meaning it has many mutations and may respond better to immunotherapy). The goal is to shrink the cancer and potentially make it removable by surgery.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.